» Articles » PMID: 35251344

Cervical Cancer, Geographical Inequalities, Prevention and Barriers in Resource Depleted Countries

Overview
Journal Oncol Lett
Specialty Oncology
Date 2022 Mar 7
PMID 35251344
Authors
Affiliations
Soon will be listed here.
Abstract

Cervical cancer (CC) remains a current global issue, with >90% of cervical cancer cases being attributed to human papilloma virus (HPV). The highest burden of cervical cancer is reported in resource-depleted geographical areas with a high incidence of HPV infection. Recent developments in primary prevention include vaccinations against specific strains of HPV and the psychoeducation of the public. Yet, despite the availability of vaccinations, there is high incidence of both HPV and cervical cancer in developing countries, which is attributed to a multitude of barriers including inaccessibility to expensive vaccines. With regards to secondary prevention, progress is actively being made to develop more effective methods of screening and to specifically address the needs of low-income countries. In the past few years, more novel screening methods, such as self-assessment kits, immunohistochemistry and methylation marker analysis, have been developed. Barriers to screening in resource-depleted countries include limited financial resources and infrastructure to develop screening programmes, a lack of screening programmes that are accessible to populations, inadequate training of healthcare teams and stigma related to medical examinations performed as part of screening. Developing primary and secondary prevention programs, as well as addressing the barriers involved in countries with low socioeconomic levels, can drastically reduce morbidity and mortality rates associated with cervical cancer, thus reducing the burden associated with this gynaecological malignancy.

Citing Articles

Optical imaging for screening and early cancer diagnosis in low-resource settings.

Richards-Kortum R, Lorenzoni C, Bagnato V, Schmeler K Nat Rev Bioeng. 2024; 2(1):25-43.

PMID: 39301200 PMC: 11412616. DOI: 10.1038/s44222-023-00135-4.


Risk factors for the development of cervical cancer: analysis of the evidence.

Luvian-Morales J, Gutierrez-Enriquez S, Granados-Garcia V, Torres-Poveda K Front Oncol. 2024; 14:1378549.

PMID: 38846977 PMC: 11153748. DOI: 10.3389/fonc.2024.1378549.


The association of cervical cancer screening and quality of care: A systematic analysis of the Global Burden of Disease Study 2019.

Wang M, Jin Y, Zheng Z J Glob Health. 2023; 13:04090.

PMID: 37622720 PMC: 10451102. DOI: 10.7189/jogh.13.04090.


Upregulation of TMEM40 is associated with the malignant behavior and promotes tumor progression in cervical cancer.

Zhang Z, Liu F, Zhang H, Liu B, Zheng S, Ye W Discov Oncol. 2023; 14(1):43.

PMID: 37052818 PMC: 10102277. DOI: 10.1007/s12672-023-00648-9.


Which is the best management for women with normal cervical cytologic findings despite positivity for non-16/18 high risk human papillomaviruses?.

Wu M, Ma X, Li H, Li B, Wang C, Fan X Front Public Health. 2022; 10:950610.

PMID: 36438260 PMC: 9682294. DOI: 10.3389/fpubh.2022.950610.


References
1.
Urasa M, Darj E . Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. Afr Health Sci. 2011; 11(1):48-57. PMC: 3092321. View

2.
Calderon-Mora J, Byrd T, Alomari A, Salaiz R, Dwivedi A, Mallawaarachchi I . Group Versus Individual Culturally Tailored and Theory-Based Education to Promote Cervical Cancer Screening Among the Underserved Hispanics: A Cluster Randomized Trial. Am J Health Promot. 2019; 34(1):15-24. DOI: 10.1177/0890117119871004. View

3.
Ngu S, Wei N, Kwan T, Chu M, Tse K, Chan K . Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial. J Psychosom Obstet Gynaecol. 2017; 39(2):146-155. DOI: 10.1080/0167482X.2017.1312335. View

4.
Lekoane K, Kuupiel D, Mashamba-Thompson T, Ginindza T . Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review. BMC Cancer. 2019; 19(1):563. PMC: 6558783. DOI: 10.1186/s12885-019-5781-3. View

5.
Bosch F, Robles C, Diaz M, Arbyn M, Baussano I, Clavel C . HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2015; 13(2):119-32. DOI: 10.1038/nrclinonc.2015.146. View